SEATTLE, March 29, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, is releasing multiple new products at the American Association of Cancer Research (AACR) Meeting. The new products build on NanoString’s existing portfolio of products that leverage genomics and proteomics to advance precision oncology.
“We continue to enhance the capabilities and expand the content for our nCounter platform. Our goal is to deliver best-in-class solutions that address the complex challenges that are inherent in precision oncology,” said Brad Gray, president and chief executive officer of NanoString Technologies.
New products released include the following:
- The nCounter Low RNA Input Kit enables nCounter Gene Expression analysis to be performed with sample inputs ranging from 1-10 ng, depending on sample quality. The kit is compatible with NanoString’s panel products as well as custom offerings. It utilizes Multiplexed Target Enrichment (MTE) to linearly amplify mRNA sample transcripts and is compatible with a wide range of sample types including Formalin Fixed Parafin Embedded (FFPE) tissue.
- The nCounter® Vantage 3D™ RNA MAPK-PI3K Pathways Panel provides a curated gene set measuring transcriptional activity of the MAPK and PI3K pathways on the nCounter® platform. Seminal publications focused on MAPK and PI3K research and signature development were collated and scored to develop this panel, which captures the diverse set of biological functions that the MAPK and PI3K pathways modulate. As part of the Vantage 3D™ portfolio, these panels pair with the Vantage 3D DNA SNV and Protein Solid Tumor Panels for integrated DNA, RNA, and protein quantification in solid tumor research.
- The Intracellular Compatible Universal Cell Capture Kit enables the nCounter Vantage 3D RNA:Protein Immune Cell Signaling Assay with as few as 20,000 cells for expression analysis of 770 RNA and 26 key intracellular proteins, including cytokines, chemoattractants, and transcription factors. In combination with the new Low RNA Input Kit, both the Vantage 3D RNA:Protein Immune Cell Profiling and Immune Cell Signaling Assay provide in depth immune characterization from minimal sample.
- The nCounter Myeloid Innate Immunity Panels provide researchers studying the role of myeloid innate immune response in cancer and other diseases a tool for rapid, comprehensive gene expression profiling of human or mouse RNA. Designed in partnership with Lisa Coussens, Ph.D., of Oregon Health and Sciences University, the panels enable quantitative evaluation of heterogeneous myeloid cell populations based on the differentiation and maturation status as well as functional activities.
NanoString will be exhibiting at AACR (booth# 3115) and hosting a workshop entitled “Powering Precision Oncology Research with 3D Biology Technology: High Plex Multi-Analyte Profiling on FFPE with Spatial Resolution” at 10:00 AM on Monday April 3. NanoString is also featured in more than 50 presentations and posters that will be presented throughout the conference.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,500 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company is collaborating with multiple biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential to discover new biomarkers and diagnostic tests using the company's nCounter Vantage assays and the timing of nCounter Vantage product evaluation programs and commercial launches. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include statements about the capabilities of our products; the timelines for commercial launch; market acceptance of our products; delays or denials of regulatory approvals or clearances for products or applications; delays or denials of reimbursement for diagnostic products; the impact of competition; the impact of expanded sales, marketing, product development and clinical activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or clinical studies; adverse conditions in the general domestic and global economic markets; as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, 3D Biology, nCounter Vantage and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.